FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
Progenics Pharma (NASDAQ: PGNX) reported Q1 EPS of ($0.18), $0.05 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $3.27 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
... More
